Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.

Thomson, A B

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. [electronic resource] - Alimentary pharmacology & therapeutics Dec 1995 - 673-83 p. digital

Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0269-2813

10.1111/j.1365-2036.1995.tb00438.x doi


Adult
Aged
Aminosalicylic Acids--adverse effects
Anti-Inflammatory Agents, Non-Steroidal--therapeutic use
Canada
Colitis--drug therapy
Crohn Disease--drug therapy
Double-Blind Method
Europe
Female
Humans
Ileitis--drug therapy
Male
Mesalamine
Middle Aged
South Africa